Lifecare ASA

Regulatory Filings • Mar 20, 2025

Lifecare scientific updates: CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025

Lifecare scientific updates: CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025

Bergen, Norway, 20 March 2025 -- Lifecare ASA (LIFE) is a medical sensor

company advancing product development for the next-generation Continuous

Glucose Monitoring (CGM). This week, Lifecare successfully hosted a

high-profile symposium, contributed to a global consensus recommendation

alongside Novo Nordisk, and is set to present data at the Advanced

Technologies & Treatment for Diabetes (ATTD) conference in Amsterdam.

Lifecare CGM symposium at Eitri, Haukeland University Hospital

17 March 2025 Lifecare brought together world-renowned experts for the

Lifecare CGM-Symposium 2025 at Eitri, Haukeland University Hospital in Bergen,

Norway. Professor David Klonoff (Diabetes Research Institute, Mills-Peninsula

Medical Center, San Mateo and UCSF, CA, USA), Niels Ejskjær (Aalborg

University Hospital), Simon Dankel (University of Bergen), and Andreas

Pfützner (Lifecare and DTMD University, Luxembourg) shared insights on the

evolution of Continuous Glucose Monitoring, discussing past, present, and

future perspectives. The symposium explored state-of-the-art CGM technologies,

including Lifecare's proprietary osmotic-pressure-based sensor, a novel

approach aiming to revolutionize glucose monitoring with increased accuracy

and longevity.

Among the key topics covered at the symposium were:

* Next-generation CGM devices -- including nano-printed,

osmotic-pressure-based sensors from Lifecare.

* Glucose-dependent insulin -- an emerging technology with the potential to

deliver insulin that only activates at high glucose levels.

* AI-powered Glycemic Risk Index (GRI) -- a software tool that synthesizes

large amounts of CGM data to aid physicians in making faster, data-driven

decisions.

* In-hospital diabetes management -- addressing the inadequacies in current

clinical protocols.

"Technology is key to transforming diabetes care", says Joacim Holter, CEO of

Lifecare. "This symposium was an excellent platform to discuss the latest

advancements and Lifecare's role in the future of CGM innovation."

In addition to the scientific program, Marta Helgidottir, a representative

from the Norwegian Diabetes Association, shared her personal story of being a

mother to a four -year-old girl with Type 1 diabetes.

- The patient perspective is fundamentally important for the work at Lifecare

and such testimonies are highly valued. The Lifecare team looks forward to the

next CGM symposium, says CEO Joacim Holter.

Lifecare supports the Diabetes Technology Society global consensus on GLP-1

and Type 1 Diabetes.

Lifecare has contributed as a sponsor, alongside Novo Nordisk, for a Consensus

Recommendations on the use of GLP-1 Receptor Agonists in Type 1 Diabetes,

hosted by the Diabetes Technology Society and chaired by Professor David

Klonoff (Diabetes Research Institute, Mills-Peninsula Medical Center, San

Mateo and UCSF, CA, USA) and Professor Viral N. Shah (Indiana University

School of Medicine, IN, USA).

This significant global initiative, spearheaded by 19 leading global diabetes

technology experts, aims to establish clinical guidelines for integrating

GLP-1 receptor agonists into type 1 diabetes management, offering new

therapeutic avenues for improved glycemic control and patient outcomes.

- We are happy to sponsor this publication from The Diabetes Technology

Society. These recommendations aim to guide clinicians and researchers in

optimizing the use of GLP-1RAs alongside AID systems to improve outcomes for

individuals with T1D, says CEO Joacim Holter.

For further details, visit: Diabetes Technology Society

(https://www.diabetestechnology.org/glp1t1d/).

Lifecare presents data at ATTD 2025

This week, Lifecare will showcase scientific findings at ATTD in Amsterdam,

highlighting the latest results from its Sencell CGM development program. The

Poster presentation will focus on human and veterinary studies evaluating

Lifecare's proprietary osmotic-pressure-based glucose sensor, which aims to

set a new benchmark for accuracy and longevity in CGM technology.

Study results indicate that Lifecare's Sencell sensor demonstrates a Mean

Absolute Relative Difference (MARD) of 9.6%, placing it in line with leading

commercial CGM devices. The sensor, which is designed to function for a

minimum of 6 months has successfully tracked glucose concentrations comparable

to existing needle-based CGMs, paving the way for further development in

wireless data and energy transfer.

"Our ongoing product development continues to validate the Sencell sensor's

unique capabilities," said Joacim Holter. "We are committed to delivering a

next-generation CGM solution that enhances both patient experience and

clinical outcomes."

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42